UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue ...
The US Food and Drug Administration has approved Crinecerfont for treatment of classic congenital adrenal hyperplasia, ...
Adrenal insufficiency or bilateral oophorectomy ... include transdermal testosterone or oral dehydroepiandrosterone treatment, both of which have been shown to result in significant improvements ...
In patients who have received less than 14 days of dexamethasone therapy, treatment may be abruptly ... therapy evolved to prevent adrenal insufficiency syndrome and recurrence or exacerbation ...
New guidelines on the diagnosis and management of premature ovarian insufficiency (POI) – developed by the Centre for Research Excellence in Women's Health in Reproductive Life (CRE-WHiRL) at Monash ...
UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
The field of molecular and biochemistry diagnostics of adrenal tumors is rapidly evolving, driven by the need to accurately diagnose and manage these complex conditions. Adrenal incidentalomas, which ...
New guidelines on the diagnosis and management of premature ovarian insufficiency (POI ... causation, sequelae and treatment of POI. The recommendations were developed using the best available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback